Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival


      • Development of a cardiovascular event is very common in chronic kidney disease patients.
      • Plasma endostatin levels are elevated in a large number of diseases, and may reflect endothelial cell dysfunction.
      • Endostatin levels are independently associated with the development of cardiovascular events in chronic kidney disease patients.
      • Plasma endostatin levels may improve the prediction for cardiovascular event above that of traditionally used risk factors.


      Background and aims

      Endostatin, generated from collagen XVIII, and endorepellin, possess dual activity as modifiers of both angiogenesis and endothelial cell autophagy. Plasma endostatin levels are elevated in a large number of diseases, and may reflect endothelial cell dysfunction. Few data on endostatins are available for patients with chronic kidney disease (CKD). We tested whether serum endostatin values are predictive for all-cause mortality and cardiovascular events (CVEs) in a CKD population.

      Materials and method

      A total of 519 CKD pre-dialysis patients were included. Baseline plasma endostatin levels were measured in all patients. All included patients were followed-up (time-to-event analysis) until occurrence of death, fatal or nonfatal CVEs. Fatal and nonfatal CVE including death, stroke, and myocardial infarction were recorded prospectively


      The mean age of the patients was 52.2 ± 12.3 years. There were 241 (46.4%) males, 111 (21.4%) had diabetes, 229 (44.1%) were smokers and 103 (19.8%) had a previous CVE. After a median follow-up of 46 months, 46 patients died and 172 had a new CVE. In the univariable Cox survival analysis, higher endostatin levels were associated with a higher risk for both outcomes. However, after adjusting for traditional (age, gender, smoking status, diabetes, systolic blood pressure, HDL and total cholesterol) and renal-specific (eGFR, proteinuria and hsCRP) risk factors, endostatin levels remained associated only with the CVE outcome (HR = 1.88, 95% CI 1.37–2.41 for a 1 SD increase in log endostatin values).


      Endostatin levels are independently associated with incident CVE in CKD patients, but show limited prediction abilities for all-cause mortality and CVE above traditional and renal-specific risk factors.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gansevoort R.T.
        • Correa-Rotter R.
        • Hemmelgarn B.R.
        • et al.
        Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.
        Lancet. 2013; 382: 339-352
        • Stenvinkel P.
        Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease.
        J Intern Med. 2010; 268: 456-467
        • Stenvinkel P.
        • Carrero J.J.
        • Axelsson J.
        • Lindholm B.
        • Heimburger O.
        • Massy Z.
        Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?.
        Clin J Am Soc Nephrol. 2008; 3: 505-521
        • Ferreras M.
        • Felbor U.
        • Lenhard T.
        • Olsen B.R.
        • Delaisse J.
        Generation and degradation of human endostatin proteins by various proteinases.
        FEBS Lett. 2000; 486: 247-251
        • Marneros A.G.
        • Olsen B.R.
        Physiological role of collagen XVIII and endostatin.
        FASEB J. 2005; 19: 716-728
        • Martensson J.
        • Jonsson N.
        • Glassford N.J.
        • et al.
        Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients.
        Ann Intensive Care. 2016; 6: 6
        • Bellini M.H.
        • Coutinho E.L.
        • Filgueiras T.C.
        • Maciel T.T.
        • Schor N.
        Endostatin expression in the murine model of ischaemia/reperfusion-induced acute renal failure.
        Nephrology. 2007; 12: 459-465
        • Bellini M.H.
        • Malpighi T.F.
        • Calvo F.B.
        • et al.
        Immobilized kidney 28-kDa endostatin-related (KES28kDa) fragment promotes endothelial cell survival.
        Am J Nephrol. 2010; 31: 255-261
        • Ruge T.
        • Carlsson A.C.
        • Larsson T.E.
        • et al.
        Endostatin level is associated with kidney injury in the elderly: findings from two community-based cohorts.
        Am J Nephrol. 2014; 40: 417-424
        • Gouya G.
        • Siller-Matula J.M.
        • Fritzer-Szekeres M.
        • et al.
        Association of endostatin with mortality in patients with chronic heart failure.
        Eur J Clin Invest. 2014; 44: 125-135
        • Damico R.
        • Kolb T.M.
        • Valera L.
        • et al.
        Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.
        Am J Respir Crit Care Med. 2015; 191: 208-218
        • Arnlov J.
        • Ruge T.
        • Ingelsson E.
        • Larsson A.
        • Sundstrom J.
        • Lind L.
        Serum endostatin and risk of mortality in the elderly: findings from 2 community-based cohorts.
        Arterioscler Thromb Vasc Biol. 2013; 33: 2689-2695
        • National K.F.
        K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
        Am J Kidney Dis. 2002; 39: S1-266
        • Kanbay M.
        • Siriopol D.
        • Saglam M.
        • et al.
        Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
        J Clin Endocrinol Metab. 2014; 99: E1854-E1861
        • Matthews D.R.
        • Hosker J.P.
        • Rudenski A.S.
        • Naylor B.A.
        • Treacher D.F.
        • Turner R.C.
        Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
        Diabetologia. 1985; 28: 412-419
        • Celermajer D.S.
        • Sorensen K.E.
        • Gooch V.M.
        • et al.
        Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.
        Lancet. 1992; 340: 1111-1115
        • Corretti M.C.
        • Anderson T.J.
        • Benjamin E.J.
        • et al.
        Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.
        J Am Coll Cardiol. 2002; 39: 257-265
        • Stein J.H.
        • Korcarz C.E.
        • Hurst R.T.
        • et al.
        Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine.
        J Am Soc Echocardiogr. 2008; 21 ([quiz 189–190]): 93-111
        • Pencina M.J.
        • D'Agostino R.B.
        Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.
        Stat Med. 2004; 23: 2109-2123
        • Pencina M.J.
        • D'Agostino Sr., R.B.
        • Steyerberg E.W.
        Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.
        Stat Med. 2011; 30: 11-21
        • Futrakul N.
        • Butthep P.
        • Laohareungpanya N.
        • Chaisuriya P.
        • Ratanabanangkoon K.
        A defective angiogenesis in chronic kidney disease.
        Ren Fail. 2008; 30: 215-217
        • Chen J.
        • Hamm L.L.
        • Kleinpeter M.A.
        • et al.
        Elevated plasma levels of endostatin are associated with chronic kidney disease.
        Am J Nephrol. 2012; 35: 335-340
        • Carlsson A.C.
        • Ruge T.
        • Sundstrom J.
        • et al.
        Association between circulating endostatin, hypertension duration, and hypertensive target-organ damage.
        Hypertension. 2013; 62: 1146-1151
        • Arenillas J.F.
        • Alvarez-Sabin J.
        • Montaner J.
        • et al.
        Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence.
        Stroke. 2005; 36: 92-97
        • Mitsuma W.
        • Kodama M.
        • Hanawa H.
        • et al.
        Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation.
        Am J Cardiol. 2007; 99: 494-498
        • Panchal V.R.
        • Rehman J.
        • Nguyen A.T.
        • et al.
        Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease.
        J Am Coll Cardiol. 2004; 43: 1383-1387
        • Seko Y.
        • Fukuda S.
        • Nagai R.
        Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy.
        Clin Sci. 2004; 106: 439-442
        • Bruserud O.
        • Grovan F.
        • Lindas R.
        • Blymke Moinichen C.
        • Osterhus K.K.
        Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fibroblast growth factor, leptin and endostatin.
        Scand J Clin Lab Invest. 2005; 65: 505-511
        • Silha J.V.
        • Krsek M.
        • Sucharda P.
        • Murphy L.J.
        Angiogenic factors are elevated in overweight and obese individuals.
        Int J Obes (Lond). 2005; 29: 1308-1314
        • Komorowski J.
        • Jankiewicz-Wika J.
        • Kolomecki K.
        • et al.
        Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults.
        Cytokine. 2011; 55: 56-61
        • Zeng X.
        • Chen J.
        • Miller Y.I.
        • Javaherian K.
        • Moulton K.S.
        Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis.
        J Lipid Res. 2005; 46: 1849-1859
        • Lin C.H.
        • Chen J.
        • Ziman B.
        • Marshall S.
        • Maizel J.
        • Goligorsky M.S.
        Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy?.
        Am J Physiol Heart Circ Physiol. 2014; 306: H1692-H1699
        • Kim Y.M.
        • Hwang S.
        • Kim Y.M.
        • et al.
        Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.
        J Biol Chem. 2002; 277: 27872-27879
        • Boodhwani M.
        • Nakai Y.
        • Mieno S.
        • et al.
        Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress.
        Ann Thorac Surg. 2006; 81: 634-641
        • Lauten A.
        • Majos E.
        • Muhlich A.
        • et al.
        Ischemia–reperfusion injury activates early extracellular matrix processing and expression of endostatin in the heart with differential effects of temperature.
        Basic Res Cardiol. 2009; 104: 559-569
        • O'Riordan E.
        • Mendelev N.
        • Patschan S.
        • et al.
        Chronic NOS inhibition actuates endothelial–mesenchymal transformation.
        Am J Physiol Heart Circ Physiol. 2007; 292: H285-H294
        • Isobe K.
        • Kuba K.
        • Maejima Y.
        • Suzuki J.
        • Kubota S.
        • Isobe M.
        Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model.
        Circ J. 2010; 74: 109-119
        • Givvimani S.
        • Kundu S.
        • Narayanan N.
        • et al.
        TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure.
        Arch Physiol Biochem. 2013; 119: 65-74
        • Carlsson A.C.
        • Carrero J.J.
        • Stenvinkel P.
        • et al.
        Endostatin, Cathepsin S, and Cathepsin L, and their association with inflammatory markers and mortality in patients undergoing hemodialysis.
        Blood Purif. 2015; 39: 259-265
        • Ueland T.
        • Aukrust P.
        • Nymo S.H.
        • et al.
        Predictive value of endostatin in chronic heart failure patients with poor kidney function.
        Cardiology. 2015; 130: 17-22